MajesTEC-3: Teclistamab Plus Daratumumab Improves Progression-Free and Overall Survival in Relapsed/Refractory Multiple Myeloma

Relapsed/refractory multiple myeloma (RRMM) remains a clinically challenging disease state, particularly in earlier relapse settings where depth and durability of...